Baker Bros. Advisors
$19.9B 13F equity value
91 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Baker Bros. Advisors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| INCY | Incyte Corporation | 30,762,330 | $3.5B | 17.5% |
| ONC | BeOne Medicines Ltd. | 8,801,567 | $2.5B | 12.6% |
| RVMD | Revolution Medicines, Inc. | 11,443,357 | $2.1B | 10.8% |
| MDGL | Madrigal Pharmaceuticals, Inc. | 2,143,131 | $1.2B | 5.8% |
| ACAD | ACADIA Pharmaceuticals Inc. | 42,912,904 | $1.1B | 5.5% |
| KYMR | Kymera Therapeutics, Inc. | 8,657,242 | $993M | 5.0% |
| INSM | Insmed Incorporated | 8,796,111 | $938M | 4.7% |
| CELC | Celcuity Inc. | 7,915,792 | $828M | 4.2% |
| KOD | Kodiak Sciences Inc. | 19,919,186 | $776M | 3.9% |
| RYTM | Rhythm Pharmaceuticals, Inc. | 5,604,483 | $622M | 3.1% |
Track Baker Bros. Advisors's 13F portfolio: $19.9B in reported holdings, 91 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}